Methods	The collaborative Nordic and European study randomly studied the effect of adding a platinum based chemotherapy regimen to hysterectomy and radiotherapy for women with surgically excised endometrial cancer
Participants	The latest report provides data on 63 women from 12 EORTC centres. The eligibility criteria included histologically proven endometrial cancer of any type and infiltration to more than half the myometrial thickness. Women with positive peritoneal cytology and/or positive pelvic lymph nodes were also eligible and participants must have been fit to receive combination chemotherapy, have a WHO performance status of 0 to 2, adequate bone marrow, renal, hepatic and pulmonary function and give informed consent
Interventions	Early participants in the chemotherapy arm received four courses of cisplatin = 50mg/m2 + doxorubicin 50mg/m2 or epirubicin 75mg/m2. Later in the trial, several regimens were allowed, of which cisplatin + doxorubicin, paclitaxel 175mg/m2 + epirubicin 60mg/m2 + carboplatin AUC 5, and paclitaxel 175mg/m2 + carboplatin AUC 5/6 were most popular The control group were treated by pelvic radiotherapy ± vaginal brachytherapy to a dose of 44 Gray
Outcomes	The primary outcome was relapse free survival. The secondary endpoints were: Overall survival of patients treated with either radiation alone or radiation and chemotherapy given sequentially. To evaluate the addition of chemotherapy to the standard adjuvant treatment (radiotherapy) in terms of toxicity. To study whether the pattern of relapse will be influenced by the addition of chemotherapy.
Results (OS & PFS)	see the combined EORTC and NSGO table
Results (site of recurrence)	see the combined EORTC and NSGO table
Toxicity	see the combined EORTC and NSGO table
Notes	The data are still immature and the survival curves will evolve as later recruiters reach 5 years survival. The EORTC have not yet published the full report but early data are available from ASCO presentations and a report including the MaNGO trial is in the 2010 European Journal of Cancer
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Sequence generation was organised by the EORTC headquarters using a minimisation procedure with the stratification factors for each centre
Allocation concealment (selection bias)	High risk	It is not possible to conceal treatment allocation from the participants but the treatment allocation will have been concealed from the data analysts
Blinding (performance bias and detection bias) All outcomes	Low risk	The data collection was by the EORTC data centre, an organisation of the highest scientific standard
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial has not yet been reported but the data will be analysed by the EORTC data centre, an organisation of the highest scientific standard
Selective reporting (reporting bias)	Low risk	The trial has not yet been reported but the data will be analysed by the EORTC data centre, an organisation of the highest scientific standard
Other bias	Unclear risk	The main issue are that details of the study population have not yet been formally published
Main problems with the trial as perceived by this analysis	Unclear risk	The trial has not yet been reported